New Trends in Allergy and Atopic Eczema

Editor(s): Ring J. (Munich) 
Darsow U. (Munich) 
Behrendt H. (Munich) 
Table of Contents
Vol. 96, 2012
Section title: Therapy and Management
Ring J, Darsow U, Behrendt H (eds): New Trends in Allergy and Atopic Eczema. Chem Immunol Allergy. Basel, Karger, 2012, vol 96, pp 113–119

New Strategies for Dealing with Staphylococcus aureus Colonization and the Emerging Methicillin-Resistant Staphylococcus aureus Epidemic in Atopic Dermatitis

Boguniewicz M.
Division of Pediatric Allergy-Immunology, Department of Pediatrics, National Jewish Health and University of Colorado School of Medicine, Denver, Colo., USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Atopic dermatitis is a common inflammatory skin disease and a global health problem. Patients are often colonized or infected by Staphylococcus aureus, usually by toxin-producing strains. Methicillin-resistant S. aureus (MRSA) has emerged as an important pathogen. Community-acquired MRSA, a frequent cause of skin and soft tissue infections has become epidemic. Basic skin care measures emphasizing repair and protection of the skin barrier reduce microbial colonization and decrease the need for specific antimicrobial therapy even in patients colonized by MRSA. Novel approaches directed at S. aureus colonization and prevention of infection include compounds mimicking antimicrobial peptides, vaccines targeting unique antigens and toxin-neutralizing agents.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Odhiambo JA, Williams HC, Clayton TO, Robertson CF, Asher MI: ISAAC Phase Three Study Group: Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. J Allergy Clin Immunol 2009;124:1251-8e23.
  2. Boguniewicz M, Leung DY: Recent insights into atopic dermatitis and implications for management of infectious complications. J Allergy Clin Immunol 2010;125:4-13
  3. Hanifin JM, Rajka G: Diagnostic features of atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 1980;92:44-47
  4. Boucher HW, Corey GR: Epidemiology of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008;46:S344-S349
  5. Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, Harrison LH, Lynfield R, Dumyati G, Townes JM, Craig AS, Zell ER, Fosheim GE, McDougal LK, Carey RB, Fridkin SK: Active Bacterial Core Surveillance (ABCs) MRSA Investigators: Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007;298:1763-1771
  6. Stryjewski ME, Chambers HF: Skin and soft tissue infections caused by community acquired methicillin resistant Staphylococcus aureus. Clin Infect Dis 2008;46:S368-S377
  7. Chambers HF: Community-associated MRSA resistance and virulence converge. N Engl J Med 2005;352:1485-1487
  8. Miller LG, Perdreau-Remington F, Rieg G, Mehdi S, Perlroth J, Bayer AS, Tang AW, Phung TO, Spellberg B: Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med 2005;352:1445-1453
  9. Otto M: Community-associated MRSA: a dangerous epidemic. Future Microbiol 2007;2:457-459
  10. Vandenesch F, Naimi T, Enright MC, Lina G, Nimmo GR, Heffernan H, Liassine N, Bes M, Greenland T, Reverdy ME, Etienne J: Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: worldwide emergence. Emerg Infect Dis 2003;9:978-984
  11. Voyich JM, et al: Is Panton-Valentine leukocidin the major virulence determinant in community-associated methicillin-resistant Staphylococcus aureus disease?. J Infect Dis 2006;194:1761-1770
  12. Wang R, Braughton KR, Kretschmer D, et al: Identification of novel cytolytic peptides as key virulence determinants for community-associated MRSA. Nat Med 2007;13:1510-1514
  13. Schlievert PM, Strandberg KL, Lin YC, Peterson ML, Leung DY: Secreted virulence factor comparison between methicillin-resistant and methicillin-sensitive Staphylococcus aureus, and its relevance to atopic dermatitis. J Allergy Clin Immunol 2010;125:39-49
  14. Cho SH, Strickland I, Boguniewicz M, Leung DY: Fibronectin and fibrinogen contribute to the enhanced binding of Staphylococcus aureus to atopic skin. J Allergy Clin Immunol 2001;108:269-274
  15. Stalder JF, Fleury M, Sourisse M, Rostin M, Pheline F, Litoux P: Local steroid therapy and bacterial skin flora in atopic dermatitis. Br J Dermatol 1994;131:536-540
  16. Remitz A, Kyllönen H, Granlund H, Reitamo S: Tacrolimus ointment reduces staphylococcal colonization of atopic dermatitis lesions. J Allergy Clin Immunol 2001;107:196-197
  17. Gorwitz RJ, Jernigan DB, Powers JH, Jernigan JA: and Participants in the CDC-Convened Experts’ Meeting on Management of MRSA in the Community. Strategies for clinical management of MRSA in the community: Summary of an experts’ meeting convened by the Centers for Disease Control and Prevention 2006;Available at Accessed December 122011;
  18. Boguniewicz M, Sampson H, Leung SB, Harbeck R, Leung DY: Effects of cefuroxime axetil on Staphylococcus aureus colonization and superantigen production in atopic dermatitis. J Allergy Clin Immunol 2001;108:651-652
  19. Birnie AJ, Bath-Hextall FJ, Ravenscroft JC, Williams HC: Interventions to reduce Staphylococcus aureus in the management of atopic eczema. Cochrane Database Syst Rev 2008;3:CD003871
  20. Wollenberg A, Schnopp C: Evolution of conventional therapy in atopic dermatitis. Immunol Allergy Clin N Am 2010;3:351-368
  21. Huang JT, Abrams M, Tlougan B, Rademaker A, Paller AS: Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severity. Pediatrics 2009;123:e808-e814
  22. Boguniewicz M, Nicol NH, Kelsay K, Leung DYM: A multidisciplinary approach to evaluation and treatment of atopic dermatitis. Semin Cut Med Surg 2008;27:115-127
  23. Savage PB, Li C, Taotafa U, Ding B, Guan Q: Antibacterial properties of cationic steroid antibiotics. FEMS Microbiol Lett 2002;217:1-7
  24. Ding B, Taotofa U, Orsak T, Chadwell M, Savage PB: Synthesis and characterization of peptide-cationic steroid antibiotic conjugates. Org Lett 2004;6:3433-3436
  25. Chin JN, et al: Antimicrobial activities of ceragenins against clinical isolates of resistant Staphylococcus aureus. Antimicrob Agents Chemother 2007;51:1268-1273
  26. Otto M: Targeted immunotherapy for staphylococcal infections: focus on anti-MSCRAMM antibodies. BioDrugs 2008;22:27-36
  27. Stranger-Jones YK, Bae T, Schneewind O: Vaccine assembly from surface proteins of Staphylococcus aureus. Proc Natl Acad Sci USA 2006;103:16942-16947
  28. Glowalla E, Tosetti B, Kronke M, Krut O: Proteomics-based identification of anchorless cell wall proteins as vaccine candidates against Staphylococcus aureus. Infect Immun 2009;77:2719-2729
  29. Buonpane RA, Churchill HRO, Moza B, Sundberg EJ, Peterson ML, Schlievert PM, et al: Neutralization of staphylococcal enterotoxin B by soluble, high-affinity receptor antagonists. Nat Med 2007;13:725-729
  30. Yang X, Buonpane RA, Moza B, Nur-ur Rahman AKM, Wang N, Schlievert PM, et al: Neutralization of multiple staphylococcal superantigens by a single-chain protein consisting of affinity-matured, variable domain repeats. J Invest Dermatol 2008;198:344-348

Pay-per-View Options
Direct payment This item at the regular price: USD 33.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 23.00